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Obstructive disease of the large coronary arteries is the prominent cause for angina pectoris. However,
angina may also occur in the absence of signiﬁcant coronary atherosclerosis or coronary artery spasm,
especially in women. Myocardial ischaemia in these patients is often associated with abnormalities of
the coronary microcirculation and may thus represent a manifestation of coronary microvascular
disease (CMD). Elucidation of the role of the microvasculature in the genesis of myocardial ischaemia
and cardiac damage—in the presence or absence of obstructive coronary atherosclerosis—will certainly
result in more rational diagnostic and therapeutic interventions for patients with ischaemic heart
disease. Speciﬁcally targeted research based on improved assessment modalities is needed to
improve the diagnosis of CMD and to translate current molecular, cellular, and physiological knowledge
into new therapeutic options.
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1. Introduction
Ischaemic heart disease may frequently occur in the absence
of signiﬁcant coronary atherosclerosis, especially in
women.1–3 Clinical reports suggest that in these patients,
chest pain is related to coronary microvascular disease
(CMD).4 CMD has been suggested to be present also in
many other patients after relief of signiﬁcant coronary
atherosclerosis. Cardiologists are familiar with the phenom-
enon of slow myocardial blood ﬂow in the setting of acute
myocardial infarction5 or with the occurrence of persisting
chest pain, and ischaemia, after percutaneous coronary
intervention in the absence of residual stenosis in the
culprit vessel.6
The implicit assumption in all of these patients is that
reduced perfusion in the absence of signiﬁcant stenosis
would reﬂect impairment of the myocardial microcircula-
tion. This assumption however needs conﬁrmation.
It is the aim of the present article to brieﬂy review the
current knowledge on the involvement of CMD in different
clinical scenarios and to deﬁne diagnostic approaches that
are currently available or under development to assess
CMD both invasively and non-invasively. This article has
been prepared by members of the Working Group on Coron-
ary Pathophysiology and Microcirculation of the European
Society of Cardiology (ESC) and reﬂects their expertise and
knowledge of this ﬁeld.
2. Endothelial function/dysfunction
Clinical symptoms of patients with non-obstructive coronary
disease are often poorly understood. Chest pain could be
explained by microvascular dysfunction. Abnormality of both
endothelium-dependent and -independent vasodilatation
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may be a cause of vascular dysfunction, the most frequent
cause being endothelial dysfunction.7–9
A normally functioning vascular endothelium is required for
appropriate dilatation of arteries. Endothelial cells produce
several mediators with vasorelaxing, anti-proliferative, anti-
thrombotic, and anti-adherent effects, such as nitric oxide,
prostacyclin, endothelium-derived hyperpolarizing factor,
and C-type natriuretic peptide. These factors are balanced
by the release of substances with opposing effects, such as
endothelin, thromboxaneA2, prostaglandinH2, and superoxide
anion. Impairment of endothelium-dependent dilatation shifts
a net dilator response to a variety of stimuli to a net constrictor
response.
3. Coronary microvascular disease in
different clinical scenarios
There are three broad categories related to possible abnorm-
alities of the coronarymicrocirculation. Theﬁrst is referred to
as the occurrence of ischaemic heart disease in the absence of
angiographically signiﬁcant coronary atherosclerosis and
could result from inﬂammation and/or abnormal vasomotor
regulation via endothelial-dependent and independent path-
ways.1–4 However, it should be considered that a normal or
near-normal angiography does not necessarily rule out the
presence of a large ‘hidden’ atherosclerotic burden.10,11
The second category refers to inadequate post-PCI and/or
post-thrombolysis coronary reperfusion entailing an early
phase referred to as ‘microvascular obstruction’12 possibly
involving microembolic mechanisms, and a later phase of
‘microvascular dysfunction’, whichmay represent corollaries
of reperfusion injury, including tissue oedema, neutrophil
aggregation, and free-radical release.13,14 Finally, the third
category is microvascular dysfunction in the context of epi-
cardial vessel disease.
3.1 Acute coronary syndrome in the absence
of signiﬁcant coronary atherosclerosis
This phenomenon has been considered for many years as an
angiographic curiosity. New data suggest that this is no
longer appropriate. Patients with chest pain and normal or
near-normal coronary angiograms belong to a group in
which the prognosis is not necessarily as benign as previously
reported2 especially if impaired endothelial function is diag-
nosed.15,16 Recent work revealed that the 1 year mortality
rate of patients with acute coronary syndrome (ACS) but
without obstructive coronary artery disease is high (1.0%),
but these patients have a relatively lower incidence of
death compared with patients with obstructive coronary
artery disease in the same clinical setting (3.9%).17 The
death rate in patients with chronic stable symptoms
ranges from 0.6% per year in the absence of obstructive cor-
onary lesions to 2.0% in the presence of such lesions.18,19
Patients with ACS are, therefore, usually at higher risk
than patients with stable effort-related angina even in the
absence of coronary obstructions. This demonstrates that
we need more information on mechanisms underlying myo-
cardial ischaemia and cardiac damage in patients presenting
with an ACS and non-obstructive epicardial coronary
disease. We also need reliable methods of risk stratiﬁcation
of patients with non-obstructive coronary disease.20
3.2 Chronic stable angina in patients with
angiographically smooth normal coronary arteries
Recurrent chronic stable angina in patients with angiogra-
phically smooth coronary arteries and an abnormal stress
test response has been referred to as ‘Cardiac Syndrome
X’.1,21,22 In a subset of patients with Syndrome X, microvas-
cular dysfunction can be demonstrated and this entity is
commonly referred to as ‘microvascular angina’.23
Microcirculatory dysfunction has recently been associated
with heart failure and/or diabetes and hypertension.4,5,24
Early-stage atherosclerosis is also associated with endo-
thelial dysfunction and may contribute to microvascular dys-
function in less deﬁned clinical subsets of patients.23,25,26
Finally, microvascular vasomotor dysfunction may occur
independently of epicardial disease in heart transplant reci-
pients, suggesting different entities of immune-mediated
cardiac allograft vasculopathy,27 which may have prognostic
importance for the deterioration of left ventricular func-
tion.28 A better understanding of the mechanisms of recur-
rent chronic angina in the absence of coronary disease at
angiography should allow assigning an increasing fraction
of these patients to distinct pathophysiological entities,
which, in turn, may support the development of more
speciﬁc treatment options.
3.3 Persistent/recurrent angina after successful
revascularization
In many cases, percutaneous or surgical revascularization
results in superior symptomatic relief of angina and improves
exercise tolerance compared with medical therapy, but the
beneﬁts are seldomcomplete. It is commonclinical experience
to see that a substantial portion of patients still continues to
experience symptoms under various circumstances. The long-
term effects of PCI in comparison with an alternative path of
continuedmedical treatment havebeen reviewed recently.6,29
At 5 years, 26% of patients in the PCI group and 28% of those in
the medical therapy group showed persisting angina. Similar
observations were reported in a multinational prospective
study comparing the relative beneﬁts of CABG and PCI in
patients with multivessel disease potentially amenable to
stent implantation.30 Although several mechanisms may be
considered toexplain thepersistenceofanginaafter a revascu-
larization procedure (incomplete revascularization, graft/
PTCA failure, and disease progression in native coronary
arteries), the unexpected prevalence of angina after success-
ful revascularization supports the hypothesis that persisting
alterations of microcirculation contribute to the pathogenesis
of ischaemia.31,32
3.4 No reﬂow
In patients with acute myocardial infarction, inadequate
myocardial perfusion after successful coronary recanaliza-
tion (no reﬂow) is associated with adverse cardiovascular
events.33,34 No reﬂow may be associated with lack of
patency or with loss of anatomic integrity of microvessels.
The former is potentially reversible, whereas the latter is
associated with deﬁnitive tissue damage.5
Multiple mechanisms may account for this ﬁnding.
Necropsy studies have demonstrated the presence of
thrombi in the coronary microvasculature from patients
who died of acute myocardial infarction.35 Multiple
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mechanisms may account for this ﬁnding. Fibrinolysis gener-
ates elevated levels of free thrombin.35–37 The release of
vasoactive mediators from activated thrombocytes may
impair regional ﬂow (microvascular spasm) and contribute
to the no-reﬂow phenomenon.36,37 Oxygen free radicals gen-
erated soon after the release of the epicardial obstruction
may inactivate nitric oxide, thus impairing endothelium-
mediated vasodilatation, or directly cause microvascular
spasm.38 Flow may also be impaired by adhesion of leuko-
cytes to microvascular endothelium.39 Inadequate myocar-
dial perfusion after successful coronary recanalization is
associated with adverse cardiovascular events.33,34 No
reﬂow may be associated with lack of patency or with loss
of anatomic integrity of microvessels. The former is poten-
tially reversible, whereas the latter is associated with
deﬁnitive tissue damage.5 Although GP IIb/IIIa glycoprotein
receptor inhibition generally ameliorates deﬁcits in coron-
ary ﬂow reserve after acute myocardial infarction treated
with primary PCI40 and improves prognosis in these patients,
a potent therapeutic strategy to prevent or improve the
no-reﬂow phenomenon is still missing.
3.5 Microvascular dysfunction in the context
of epicardial vessel disease
Coronary artery stenosis decreases ﬂow reserve in the vascu-
lar bed distally to a stenotic epicardial artery.41 Even early
atherosclerotic lesions are associated with impaired endo-
thelial coronary blood ﬂow regulation.42 In addition to the
effects of a stenosis on ﬂow reserve within its own bed, cor-
onary stenosis and occlusion also decrease ﬂow reserve in
adjacent non-stenotic beds in both experimental animal
models and clinical populations.43 Importantly, global coron-
ary ﬂow reserve predicts cardiovascular events in patients
with only minimal44 or intermediate epicardial lesions.45 It
also predicts development of restenosis after coronary
stent implantation.46 Blood ﬂow-mediated shear stress on
the endothelium of epicardial vessels controls the release
of nitric oxide and other factors, regulating the vascular
milieu and therefore may interfere with progression of
atherosclerosis or restenosis development.47 The integrity
of blood ﬂow regulation in the microcirculation may thus
have potential effects on the development of epicardial
atherosclerosis.
4. Experimental assessment of coronary
microcirculation
Investigating alterations of microcirculatory function under
a variety of pathophysiological conditions is a very active
area of research, which has much contributed to our under-
standing of microcirculation. Many experimental models are
available to investigate the coronary microcirculation; each
has its own peculiarities, strengths, ﬁeld of application, and
limitations.
Rats, pigs, and dogs have been used most frequently as
models in the study of intramyocardial circulation to validate
imaging techniques, to examine postmortem pathology, to
elucidate the pathophysiology of microvascular tone, and to
study the effectiveness of pharmacological interventions in
promoting microvascular dilation. Experimental models to
study microvascular diameters and/or perfusion as well as
cellular and molecular mechanisms include (i) in situ
measurements; (ii) isolated heart preparations; (iii) isolated
vessel approaches; (iv) cultured coronary microvascular
endothelial and smooth muscle cells. Models for intravital
microscopy of the beating heart in open-chest animals have
been published more than 30 years ago.48,49 Later, microvas-
cular diametermeasurements by intravitalmicroscopy in con-
junction with luminal pressure determination have been
performed to analyse the resistance distribution within the
coronary microvasculature at rest and during dipyridamole-
induced vasodilation.50 Also, different longitudinal gradients
in the responsiveness of coronary arterioles to adenosine and
nitroglycerin,51 and in alpha-1 and -2 receptor-mediated cor-
onary constriction,52 have been identiﬁed. A needle-probe
microscope53 allowed to identify differences between
responses in epicardial vs. endocardial arterioles.54
4.1 In situ measurements
Perfusion in vivo may be measured invasively with intracor-
onary Doppler wires or with ﬂow sensors positioned around
the vessel in open-chest preparation or non-invasively with
positron emission tomography (PET) and magnetic resonance
imaging (MRI). Many of these techniques can also be applied
to human subjects in contrast to the use of radioactive or
colour-labelled microspheres, which remains the gold stan-
dard of regional myocardial blood ﬂow assessment in the
experimental setting. These methodologies have been
employed to investigate a variety of issues, such as the
loss of endothelial-dependent relaxation after ischaemia/
reperfusion and the role of oxygen radicals,55 mechanisms
of no-reﬂow phenomenon13,56 and of myocardial hiber-
nation,57 and the impact of coronary risk factors on coronary
ﬂow reserve.58
4.2 Isolated heart preparations
Ex vivo isolated heart measurements of microvascular per-
fusion (rabbit, rat, guinea pig, and mouse) allow to accu-
rately investigate intrinsic regulation of coronary blood
ﬂow in the absence of neuronal or hormonal inﬂuences
without the confounding effects of changes in haemody-
namics. Typical topics include the nitric oxide-dependent
regulation of coronary blood ﬂow59,60 and studies of the
pathways of neutrophil/vessel wall61 and neutrophil/plate-
let/vessel wall62 interactions during post-ischaemic reperfu-
sion. Arresting isolated rat hearts with tetrodotoxin also
allows for microscopic investigation of microvascular diam-
eter responses at constant metabolic demand.63
4.3 Isolated vessel approaches and cultured
coronary microvascular cells
Assessment of diameter/tone responses in arterioles typically
isolated by surgical excision of subcutaneous tissue is a very
elegant, although technically demanding, method. It can be
employed to test the reactivity proﬁle of themicrocirculation
with respect to endothelin, arachidonic acid metabolites,
catecholamines, and other vasoactive substances. This tech-
nique has also been used in humans to examine the endo-
thelial function/dysfunction of large and small arteries
essential hypertension.64,65 Recently, coronary vessels
obtained from human atrial appendages removed during car-
diopulmonary bypass were also studied.66 One step further,
cultured coronary microvascular endothelial and smooth
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muscle cells allow to characterize vascular ion channels,
which modulate vascular smooth muscle in microvessels,
and to elucidate biochemical pathways by which endogenous
vasoactive factors exert their inﬂuence.67,68
Regrettably, there are no animal models truly mimicking
non-obstructive angina or CMD; in fact, to successfully
develop such models, the underlying mechanisms need to
be better known. At the moment, useful information can
be gathered by investigating clinical conditions character-
ized by alteration of coronary artery reactivity in the
absence of overt atherosclerothic stenosis.
5. Measuring myocardial microcirculatory
perfusion in humans
5.1 Non-invasive screening for abnormal vascular
function in humans
Commonly used tests for screening for abnormal vasomotor
regulation are single photon emission computed tomography
(SPECT) stress myocardial perfusion imaging for patients
who can exercise and dipyridamole or adenosine-induced
vasodilation in conjunction with SPECT imaging or echocar-
diography for patients who cannot exercise.69–71 These
techniques suffer from the limitation that only relative com-
parison of perfusion can be made, with no absolute esti-
mates of blood ﬂow. Additional methods are promising,
including X-ray computed tomography (CT), echo Doppler,
quantitative contrast echocardiography, and indicator-based
techniques such as PETand MRI72–75 (Table 1). Such measure-
ment of tissue perfusion, however, does not assess the
microcirculation independently, in that these measures
interrogate the ﬂow resistance of both the epicardial
artery and the microcirculation. In the presence of ﬁxed
or dynamic (vasomotor tone) epicardial stenoses, microvas-
cular ﬂow resistance cannot be directly estimated. However,
some insights can be drawn. Indeed, if an intervention
lowers computed resistance in a stenoic vascular bed but
has no effect in the same patient in a non-stenotic bed, it
would be reasonable to conclude that the decline in resist-
ance observed in the stenotic bed reﬂects a change in epi-
cardial rather than microvascular resistances. Conversely,
if the non-stenotic vascular bed, but not the stenosis
region, exhibits a decline in resistance, it would be logical
to conclude that microvascular resistance in the stenostic
zone was near minimal and that epicardial resistance was
unchanged by the intervention.
6. Surrogate indexes for calculating coronary
microvascular resistance
There are some opportunities to develop surrogate indexes
of microvascular ﬂow resistance in the coronary arterial
tree on the basis of invasively measured coronary ﬂow par-
ameters. These indexes are based on coronary ﬂow par-
ameters and hampered by the fact that myocardial ﬂow
has to be measured invasively.
6.1 Coronary and fractional ﬂow reserve
Measuring theﬂowresponse to thedownstreammicrovascular
bed during the infusion of endothelium-dependent and
endothelium-independent dilators into a coronary artery
has been used to directly assess coronary microvascular func-
tion (Figure 1).16,76–78 A reduced coronary ﬂow reserve in the
context of a ‘normal’ intravascular ultrasound or normal frac-
tional ﬂow reserve indicates microcirculatory dysfunction.79
Current dual sensor pressure and ﬂow wires allow relatively
simple measurements of coronary ﬂow reserve.80–82 This
techniquemay provide further insight into coronary perfusion
physiology via assessment of the ﬂow pattern (e.g. diastolic
deceleration time, systolic ﬂow reversal) and allow to
calculate indexes of absolute coronary blood ﬂow and
microcirculatory resistance (taking into account systemic
haemodynamics and vessel size, derived by quantitative cor-
onary angiography or intracoronary ultrasound).
6.2 Index of microvascular resistance
Distal coronary pressure multiplied by the hyperaemic mean
transit time (which is inversely correlated to absolute ﬂow,
as measured simultaneously with the coronary pressure
wire) may be used to roughly estimate microvascular resist-
ance (index of microvascular resistance).83,84 Importantly,
the pressure drop is a function of the square of ﬂow across
a coronary lesion and thus is geometrically not proportion-
ally related. Changes in ﬂow resistance of the vascular
bed distal to the tip of the catheter can be detected.
However, all resistance calculations based on this technique
ignore very important physiological issues such as the true
back pressure85 in the coronary circulation and coronary
capacitance and so may not always provide an accurate esti-
mate of the parameter of interest, namely microvascular
tone. In addition, preliminary data show that blood ﬂow
values cannot be readily compared among different patients
Table 1 Techniques for cardiac assessment of microvascular function
Method Quantiﬁcation Tracer Spatial
resolution
Recording
time
Non-invasive SPECT None Radio isotopes Very low Long
PET Perfusion (mL/min/g) gold
standard
Radio isotopes
(cyclotron-generated)
Low Long
CT Perfusion (mL/min/g) Contrast agent Very high Low
MRI Perfusion (mL/min/g) Contrast agent Moderate Moderate
Ultrasound Perfusion (mL/min/g) Microbubbles High Real time
Invasive Doppler wire Flow velocity (mm/s) None Selective assessment in
target vessel territoryThermo-dilution Blood ﬂow (mL/min) Saline (body temperature)
CTFC None Contrast agent
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because the absolute resistance varies depending upon the
tissue volume supplied by the respective artery.83
6.3 Thrombolysis in Myocardial Infarction
Frame Count
The Corrected Thrombolysis In Myocardial Infarction (TIMI)
Frame Count (CTFC) provides a simple index of coronary ﬂow
and myocardial perfusion. CTFC is an established method to
provide a semiquantitative categorization of ‘epicardial’
blood ﬂow, with the implicit assumption that slow ﬂow in the
absence of signiﬁcant stenosis would reﬂect impairment of
the myocardial ‘microcirculatory’ perfusion.86 CTFC has been
used as measure of microvascular integrity and seems to
predict outcome.87 Changes in CTFC not explained by concur-
rent changes in epicardial minimal lumen diameter (MLD)
may be attributed to the resistance to ﬂow at the level of cor-
onary microcirculation. The concept of the CTFC/MLD ratio
may thus be introduced as a compositemeasure ofmicrovascu-
lar structure and function. Yet the value of this technique, too,
needs to be fully elucidated. Measurements of blood ﬂowusing
the TIMI frame count methodology require serial reproduction
in patients not undergoing PCI or thrombolysis as a control
group. These data are at present not available.
7. Peripheral indexes
One alternative approach to invasive cardiac procedures
enabling the assessment of alterations in microvascular
function and structure is based on the assumption that
microvascular alterations in peripheral tissues might
reﬂect corresponding alterations in the heart. This has
been conﬁrmed for endothelial dysfunction in patients
with systemic risk factors for atherosclerosis such as dia-
betes, hypercholesterolaemia, or hypertension88,89 and for
patients with genetic alterations of microvascular respon-
siveness.90,91 However, only few studies have systematically
assessed a direct correlation between peripheral and coron-
ary vasodilator capacity, most of them limited by comparing
different entities in the peripheral and coronary vasculature
with respect to vessel size and agonist tested. It was shown
that the peripheral perfusion response to transient forearm
ischaemia (see also what follows for details) does not corre-
late with dipyridamole-induced myocardial hyperaemia.92
This might indicate different mechanisms of microvascular
activation or regulation and advocate adequate care in
respective extrapolations. However, peripheral techniques
as summarized in what follows (Table 2) are less invasive
and/or less expensive and time consuming compared with
coronary catheterization or non-invasive screening strat-
egies and may allow a more direct assessment of involved
microvascular mechanisms.
7.1 Brachial artery post-ischaemic reﬂow
Brachial artery dilation in response to different stimuli can be
measured with high-resolution ultrasound scanners. To test
endothelium-dependent dilatation, ﬂow changes are
induced by forearm ischaemia followed by post-ischaemic
hyperaemic reﬂow. In subjects with intact endothelial func-
tion, this typically results in a brachial artery diameter
increase of 10%, and its exact quantiﬁcation requires con-
siderable technical skill and experience.93 Data obtained
are then compared with the diameter response after sublin-
gual application of glyceryl trinitrate, an endothelium-inde-
pendent dilator. This technique is non-invasive, but it
assesses endothelial function in a large conduit artery and
not in microvessels. Nevertheless, the results seem to corre-
late with responses in skin microcirculation.94
7.2 Venous occlusion plethysmography
In order to assess microvascular endothelial function by
venous occlusion plethysmography, the brachial artery is
Figure 1 Set-up of intracoronary Doppler measurements of the coronary microcirculation. Blood ﬂow velocity (APV, average peak velocity) as well as ﬂow pat-
terns (e.g. DT, diastolic deceleration time or systolic ﬂow reversal) may be assessed. Volumentric blood ﬂow may be calculated with additional assessment of
coronary lumen area, approximated from quantitative coronary angiography. Vasoreactivity of the coronary microcirculation can be expressed as change of
coronary blood ﬂow in response to different stimuli (e.g. acetylcholine for endothelial stimulation or adenosine for maximal vasodilator capacity). Assuming
constant epicardial vessel size, coronary ﬂow reserve may be expressed as the ratio between maximal (adenosine-induced) and basal APV (modiﬁed, with
permission from Urban & Vogel, Munich, from Schachinger V, Zeheir AM. Coronary microcirculation. Pathophysiology, clinical relevance, and importance for
regenerative therapy after myocardial infarction. Herz 2005;30:641–650).
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cannulated for the infusion of endothelium-dependent
(e.g. acetylcholine) and -independent (e.g. Na-nitroprusside)
vasodilators, rendering this techniquemoderately invasive. It
has been successfully used to demonstrate the beneﬁcial
effects of statins95 or a third generation b-blocker96 on endo-
thelial function in patients with hypercholesterolaemia and
hypertension, respectively. Moreover, vasodilator capacity
of the peripheral microcirculation assessed by venous occlu-
sion plethysmography predicts cardiovascular events in
patients with stable coronary artery disease97 or heart
failure,98 aswell as in ACS,with those patients at highest long-
term risk inwhomACS-associated impairment of themicrocir-
culation does not recover within the following weeks.99
Recently, ﬁnger plethysmography has been introduced,
which provides further information on pulsatile ﬂow patterns
and allows the assessment of non-invasive stimuli (reactive
hyperaemia).
7.3 Laser Doppler ﬂuxmetry
Laser Doppler ﬂuxmetry (LDF) is becoming increasingly
popular for the estimation of skin microvascular blood
ﬂow.100 The surface investigated is illuminated with a laser
spot. The frequency of the laser light is altered by multiple
reﬂections at ﬂowing red blood cells. The resulting fre-
quency shift in light reﬂected from the tissue is proportional
to the product of red cell number and ﬂow velocity (equal to
a ﬂux) in the sample region, which is usually a half sphere
with a diameter of 1 mm. Since the local perfusion in
the skin is very heterogeneous, it is helpful to assess
larger areas of the tissue surface by two-dimensional scan-
ning LDF imaging. Additional information on microvascular
function may be obtained by spectral analysis of the laser
Doppler ﬂux time series using wavelet transforms. Oscil-
lations in skin perfusion with frequencies around 0.1 and
0.01 Hz are considered to reﬂect myogenic and endothelial
activities, respectively.101
In combinationwith local drugapplicationby iontophoresis,
the LDF technique allows for non-invasive study of microvas-
cular responses to a variety of pharmacological stimuli. Ion-
tophoresis relies on drug molecules carrying a positive or
negative charge which migrate across the skin when a
respective potential is applied, in direct proportion to the
current applied. Thus minute quantities of a vasoactive drug
can be administered to the microvasculature under investi-
gation in a controlled fashion, without causing systemic
effects. Acetylcholine and Na-nitroprusside are typical sub-
stances to assess endothelium-dependent and -independent
vasodilator responses.102,103 In contrast to the techniques dis-
cussed earlier, this method also allows for the application of
vasoconstrictors. Alpha-adrenergic vasoregulation has been
analysed using iontophoretic delivery of tyramine, phentola-
mine, bretylium, and norepinephrine.103 Interestingly, ionto-
phoretically delivered urotensin II may induce vasodilation in
the skinmicrovasculature of healthy control subjects but con-
striction in patients with chronic heart failure.104
Thus, iontophoresis in conjunction with laser Doppler
ﬂowmetry or imaging seems most attractive for detailed
study of peripheral microvascular function because it is
not only completely non-invasive but also allows for the
assessment of endothelium-dependent and -independent
vasodilator reserve and of vasoconstrictor sensitivity.
Table 2 Techniques for peripheral assessment of microvascular function and structure
Method Target vessels Stimulus Comments
Non-invasive Brachial artery post-ischaemic
reﬂow
Conduit artery Shear stress Validated to predict clinical
outcome
Laser Doppler ﬂux (imaging)/
iontophoresis
Cutaneous microvessels Vasoactive drugs Iontophoresis: local application of
a broad selection of drugs;
current may have direct effect
on local microvascular tone
Clinical intravital microscopy Cutaneous, mucosal, or retinal
microvessels
None Information on microvascular
structure and function; limited
range of tissues and parameters
to be analysed
Invasive Venous occlusion
plethysmography (forearm
blood ﬂow)
All forearm microvessels Vasoactive drugs Validated to predict clinical
outcome; problem: systemic
recirculation of drugs
Biopsy Subcutaneous/ muscular
microvessels
None Analysis of microvascular
structure; no functional
information
Figure 2 Laser Doppler ﬂux tracings of skin perfusion in a patient with Par-
vovirus B19-induced cardiomyopathy (B19) and a healthy subject (Control)
during 5 min of rest and 10 min of iontophoretic application of acetylcholine
(Ach) and Na-nitroprusside (NP) at 0.02 mA.
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Figure 2 shows an example of laser Doppler ﬂux tracings of
skin perfusion in a patient with Parvovirus B19-induced
cardiomyopathy.
7.4 Clinical intravital microscopy
In addition to functional deﬁcits, apparent microvascular
dysfunction may also be due to structural alterations of
the microvasculature such as rarefaction and/or remodel-
ling.105,106 Evaluation of microvascular density requires
direct visualization of microvascular networks by clinical
intravital microscopy, which is possible only in select
tissues. Capillaroscopy of the nailfold or oral tissues (gingi-
val, sublingual, or buccal mucosa) allows to study capillary
morphology, capillary density, and capillary blood vel-
ocity.107–109 The introduction of new clinical intravital
microscopes (e.g. orthogonal polarization spectral imaging)
has improved image quality and ease of application and
renders additional tissues such as sublingual or buccal
mucosa accessible.110 Speciﬁc image analysis approaches
additionally allow the measurement of arteriolar or
venular blood ﬂow velocity111 and pulsatility.112
Arteriolar morphology can also be analysed by retino-
graphy.89 Focal or generalized luminal narrowing, as well
as arteriovenous nicking, i.e. the indentation and displace-
ment of venules by crossing arterioles owing to structural
changes in the arteriolar wall, has been associated with
hypertension,113 metabolic syndrome,114 coronary heart
disease,115 and stroke.116 The major disadvantage of using
retinography for the analysis of arteriolar remodelling is
the qualitative nature of the results. A common problem
of all intravital microscopy approaches lies in the difﬁculty
of extracting quantitative data from the images, which
usually requires time consuming off-line analysis of digitized
video sequences.
7.5 Subcutaneous biopsy
In order to obtain quantitative data on arteriolar wall thick-
ness to lumen ratio, histological analysis of tissue from
biopsies is indispensable. In contrast to cardiac tissue, sub-
cutaneous fat or gluteal muscle specimens can be collected
in sufﬁcient quantities with little discomfort to the
patients.117 To support the assumption that microvascular
alterations occur not only in the heart or the brain but in
all tissues throughout the body, results obtained in these
specimens can be compared with retinography ﬁndings and
with functional data obtained in the coronary and in periph-
eral circulations. The same specimens may also be used to
investigate the mechanisms responsible for the observed
morphological alterations.118
8. Perspectives
Although many studies have supported the role of CMD in
explaining chest pain symptoms in a variety of clinical
settings, convincing evidence of a causal relationship
between myocardial ischaemia and CMD and of its pathophy-
siological mechanisms is sparse. We therefore strongly
emphasize that investigations designed to elucidate the
regulation of the coronary microcirculation in health and
disease should incorporate the best technological advances
in molecular biology, biochemistry, imaging, and physiologi-
cal measurements.
Future research needs to encompass both basic and clini-
cal investigations and to compare peripheral investigations
of microcirculation with parallel measurements in the
heart. Development and testing of new and improved diag-
nostic procedures for CMD are needed as well. Currently,
the coronary microcirculation moves into the focus of new
therapeutic strategies of cardiac disease driven by recent
insights into, e.g. endothelial effects of drugs such as
statins or ACE-inhibitors, or the restorative function of
endothelial progenitor cells119,120 and haematopoietic
stem/progenitor cells. Established and experimental thera-
pies for the prevention and treatment of microvascular dys-
function should be tested in animal and cell-based models.
In addition, clinically oriented investigations will be indis-
pensable to understand the role of the coronary microcircu-
lation in cardiac disease and to gain more precise insights
into the relationships between coronary microvascular dys-
function, inducible myocardial ischaemia, and adverse
outcome. Areas such as genetic predisposition to microvas-
cular disease in response to hypertension and/or other car-
diovascular risk factors also deserve emphasis.
9. Conclusions
The authors perceive that there is an impressive lack of
clinical and pathophysiological information on the role of
CMD in cardiac disease. This is in part due to the gap
between current experimental studies of the coronary
microcirculation and clinical investigations in this area.
Increased collaboration between basic science and
clinical-oriented researchers should help bridging this gap
and help develop improved experimental and clinical
approaches to assess and treat CMD.
Conﬂict of interest: none declared.
Funding
None.
References
1. Kaski JC. Pathophysiology and management of patients with chest pain
and normal coronary arteriograms (cardiac syndrome X). Circulation
2004;109:568–572.
2. Bugiardini R, Bairey Merz CN. Angina with ‘normal’ coronary arteries: a
changing philosophy. JAMA 2005;293:477–484.
3. Lanza GA. Cardiac syndrome X: a critical overview and future perspec-
tives. Heart 2007;93:159–166.
4. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med
2007;356:830–840.
5. Galiuto L, Gabrielli FA, Lombardo A, La TG, Scara A, Rebuzzi AG et al.
Reversible microvascular dysfunction coupled with persistent myocar-
dial dysfunction: implications for post-infarct left ventricular remodel-
ing. Heart 2006;93:565–571.
6. Poole-Wilson PA, Pocock SJ, Fox KA, Henderson RA, Wheatley DJ,
Chamberlain DA et al. Interventional versus conservative treatment in
acute non-ST elevation coronary syndrome: time course of patient man-
agement and disease events over one year in the RITA 3 trial. Heart
2006;92:1473–1479.
7. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latiﬁ R et al.
Short-term cholesterol lowering decreases size and severity of perfusion
abnormalities by positron emission tomography after dipyridamole in
patients with coronary artery disease. A potential noninvasive marker
of healing coronary endothelium. Circulation 1994;89:1530–1538.
8. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-
convertingenzyme inhibition reducesplasmaasymmetricdimethylarginine
Assessing the coronary microcirculation 171
and improves endothelial nitric oxide bioavailability and coronary micro-
vascular function in patients with syndrome X. Am J Cardiol 2002;90:
974–982.
9. Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery
disease and coronary vasomotion. Circulation 2001;103:E1–E6.
10. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM et al.
High prevalence of coronary atherosclerosis in asymptomatic teenagers
and young adults: evidence from intravascular ultrasound. Circulation
2001;103:2705–2710.
11. Jeremias A, Ge J, Erbel R. New insight into plaque healing after plaque
rupture with subsequent thrombus formation detected by intravascular
ultrasound. Heart 1997;77:293.
12. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000;
36:22–24.
13. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment
of regional myocardial perfusion after initial restoration of postischemic
blood ﬂow. Circulation 1989;80:1846–1861.
14. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL.
Neutrophils are primary source of O2 radicals during reperfusion after
prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001;
280:H2649–H2657.
15. Herrmann J, Lerman A. The endothelium: dysfunction and beyond.
J Nucl Cardiol 2001;8:197–206.
16. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial
function predicts future development of coronary artery disease: a
study of women with chest pain and normal coronary angiograms. Circu-
lation 2004;109:2518–2523.
17. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for man-
agement of acute coronary syndrome: risk stratiﬁcation of patients with
minimal disease or normal ﬁndings on coronary angiography. Arch Intern
Med 2006;166:1391–1395.
18. Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G et al. Per-
sistent chest pain predicts cardiovascular events in women without
obstructive coronary artery disease: results from the
NIH-NHLBI-sponsored Women’s Ischaemia Syndrome Evaluation (WISE)
study. Eur Heart J 2006;27:1408–1415.
19. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N
et al. Gender differences in the management and clinical outcome of
stable angina. Circulation 2006;113:490–498.
20. Bugiardini R, Badimon L, Collins P, Erbel R, Fox K, Hamm C et al. Angina
‘normal’ coronary angiography vascular dysfunction: risk assessment
strategies. PLoS Med 2007;4:e12.
21. Kemp HG Jr. Left ventricular function in patients with the anginal syn-
drome and normal coronary arteriograms. Am J Cardiol 1973;32:
375–376.
22. Kaski JC, Crea F, Nihoyannopoulos P, Hackett D, Maseri A. Transient myo-
cardial ischemia during daily life in patients with syndrome X. Am J
Cardiol 1986;58:1242–1247.
23. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanﬁeld JE. Early endo-
thelial dysfunction in adults at risk from atherosclerosis: different
responses to L-arginine. J Am Coll Cardiol 1998;32:110–116.
24. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in
hypertension: a new target for treatment? Circulation 2001;104:
735–740.
25. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC
Jr. Endothelin in coronary endothelial dysfunction and early athero-
sclerosis in humans. Circulation 1995;92:2426–2431.
26. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of
the coronary microvasculature is associated with coronary blood ﬂow
regulation in patients with early atherosclerosis. Circulation 1991;84:
1984–1992.
27. Weis M, von SW. Coronary artery disease in the transplanted heart. Annu
Rev Med 2000;51:81–100.
28. Weis M, Hartmann A, Olbrich HG, Griher AM. Prognostic signiﬁcance of
coronary ﬂow reserve on left ventricular ejection fraction in cardiac
transplant recipients. Transplantation 1998;65:103–108.
29. Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR,
Wheatley DJ et al. 5-year outcome of an interventional strategy in
non-ST-elevation acute coronary syndrome: the British Heart Foun-
dation RITA 3 randomised trial. Lancet 2005;366:914–920.
30. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM
et al. Three-year outcome after coronary stenting versus bypass
surgery for the treatment of multivessel disease. Circulation 2004;
109:1114–1120.
31. Marzilli M, Sambuceti G, Fedele S, L’Abbate A. Coronary microcircula-
tory vasoconstriction during ischemia in patients with unstable angina.
J Am Coll Cardiol 2000;35:327–334.
32. Sambuceti G, Marzilli M, Fedele S, Marini C, L’Abbate A. Paradoxical
increase in microvascular resistance during tachycardia downstream
from a severe stenosis in patients with coronary artery disease: reversal
by angioplasty. Circulation 2001;103:2352–2360.
33. Glazier JJ. Attenuation of reperfusion microvascular ischemia by
aqueous oxygen: experimental and clinical observations. Am Heart J
2005;149:580–584.
34. Peterson ED, Shaw LJ, Califf RM. Risk stratiﬁcation after myocardial
infarction. Ann Intern Med 1997;126:561–582.
35. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part II:
evolving concepts in pathophysiology, diagnosis, and treatment. Circu-
lation 2004;109:310–315.
36. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of pros-
taglandins and thromboxane into the coronary circulation in patients
with ischemic heart disease. N Engl J Med 1981;304:685–691.
37. Rucker M, Schafer T, Roesken F, Spitzer WJ, Bauer M, Menger MD. Local
heat-shock priming-induced improvement in microvascular perfusion in
osteomyocutaneous ﬂaps is mediated by heat-shock protein 32. Br J
Surg 2001;88:450–457.
38. Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takeshita A. Coronary
microvascular spasm causes myocardial ischemia in patients with vasos-
pastic angina. J Am Coll Cardiol 2002;39:847–851.
39. Christiansen JP, Leong-Poi H, Klibanov AL, Kaul S, Lindner JR. Noninva-
sive imaging of myocardial reperfusion injury using leukocyte-targeted
contrast echocardiography. Circulation 2002;105:1764–1767.
40. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M et al.
Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary
ﬂow and left ventricular function after the placement of
coronary-artery stents in acute myocardial infarction. Circulation
1998;98:2695–2701.
41. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary
vasomotor tone in humans. Progressive endothelial dysfunction with
different early stages of coronary atherosclerosis. Circulation 1991;
83:391–401.
42. Schachinger V, Britten MB, Elsner M, Walter DH, Scharrer I, Zeiher AM. A
positive family history of premature coronary artery disease is associ-
ated with impaired endothelium-dependent coronary blood ﬂow regu-
lation. Circulation 1999;100:1502–1508.
43. Sambuceti G, Marzullo P, Giorgetti A, Neglia D, Marzilli M, Salvadori P
et al. Global alteration in perfusion response to increasing oxygen con-
sumption in patients with single-vessel coronary artery disease. Circula-
tion 1994;90:1696–1705.
44. Britten MB, Zeiher AM, Schachinger V. Microvascular dysfunction in
angiographically normal or mildly diseased coronary arteries predicts
adverse cardiovascular long-term outcome. Coron Artery Dis 2004;15:
259–264.
45. Chamuleau SA, Tio RA, de Cock CC, de Muinck ED, Pijls NH, van
Eck-Smit BL et al. Prognostic value of coronary blood ﬂow velocity
and myocardial perfusion in intermediate coronary narrowings and mul-
tivessel disease. J Am Coll Cardiol 2002;39:852–858.
46. Haude M, Baumgart D, Verna E, Piek JJ, Vrints C, Probst P et al. Intra-
coronary Doppler- and quantitative coronary angiography-derived
predictors of major adverse cardiac events after stent implantation. Cir-
culation 2001;103:1212–1217.
47. Cooke JP, Tsao PS. Go with the ﬂow. Circulation 2001;103:2773–2775.
48. Steinhausen M, Tillmanns H, Thederan H. Microcirculation of the epicar-
dial layer of the heart. Pﬂugers Arch 1978;378:9–14.
49. Tillmanns H, Ikeda S, Hansen H, Sarma JSM, Fauvel J-M, Bing RJ. Micro-
circulation in the ventricle of the dog and turtle. Mol Cell 1974;34:
561–569.
50. Chilian WM, Layne SM, Klausner EC, Eastham D, Marcus ML. Redistribu-
tion of coronary microvascular resistance produced by dipyridamole. Am
J Physiol 1989;256:H383–H390.
51. Habazettl H, Vollmar B, Christ M, Baier H, Conzen PF, Peter K. Hetero-
geneous microvascular coronary vasodilation by adenosine and nitrogly-
cerin in dogs. J Appl Physiol 1994;76:1951–1960.
52. Chilian WM. Functional distribution of alpha 1- and alpha 2-adrenergic
receptors in the coronary microcirculation. Circulation 1991;84:
2108–2122.
53. Yada T, Hiramatsu O, Kimura A, Goto M, Ogasawara Y, Tsujioka K et al. In
vivo observation of subendocardial microvessels of the beating porcine
heart using a needle-probe videomicroscope with a CCD camera. Mol
Cell 1993;72:939–946.
A.R. Pries et al.172
54. Merkus D, Vergroesen I, Hiramatsu O, Tachibana H, Nakamoto H,
Toyota E et al. Stenosis differentially affects subendocardial and sube-
picardial arterioles in vivo. Am J Physiol Heart Circ Physiol 2001;280:
H1674–H1682.
55. Mehta JL, Nichols WW, Donnelly WH, Lawson DL, Saldeen TG. Impaired
canine coronary vasodilator response to acetylcholine and bradykinin
after occlusion-reperfusion. Circ Res 1989;64:43–54.
56. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N
et al. Effects of tissue factor induced by oxygen free radicals on coron-
ary ﬂow during reperfusion. Nat Med 1996;2:35–40.
57. Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G et al. Persistent
stunning induces myocardial hibernation and protection: ﬂow/function
and metabolic mechanisms. Circ Res 2003;92:1233–1239.
58. Rosen BD, Lima JA, Nasir K, Edvardsen T, Folsom AR, Lai S et al. Lower
myocardial perfusion reserve is associated with decreased regional left
ventricular function in asymptomatic participants of the multi-ethnic
study of atherosclerosis. Circulation 2006;114:289–297.
59. Giraldez RR, Panda A, Xia Y, Sanders SP, Zweier JL. Decreased nitric-
oxide synthase activity causes impaired endothelium-dependent relax-
ation in the postischemic heart. J Biol Chem 1997;272:21420–21426.
60. Paolocci N, Biondi R, Bettini M, Lee CI, Berlowitz CO, Rossi R et al.
Oxygen radical-mediated reduction in basal and agonist-evoked NO
release in isolated rat heart. J Mol Cell Cardiol 2001;33:671–679.
61. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The
anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac
reperfusion injury. J Cardiovasc Pharmacol 2005;46:89–98.
62. Kupatt C, Habazettl H, Hanusch P, Wichels R, Hahnel D, Becker BF et al.
c7E3Fab reduces postischemic leukocyte–thrombocyte interaction
mediated by ﬁbrinogen. Implications for myocardial reperfusion
injury. Arterioscler Thromb Vasc Biol 2000;20:2226–2232.
63. Goebel S, Kuebler WM, Cornelissen AJM, Kuppe H, Pries AR, Habazettl H.
In situ analysis of coronary terminal arteriole diameter responses: tech-
nical report of a new experimental model. J Vasc Res 2003;40:442–448.
64. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function
in large and small arteries in human essential hypertension. J Hypertens
2001;19:415–420.
65. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial
structure and endothelial dysfunction in human essential hypertension
by the angiotensin receptor antagonist losartan. Circulation 2000;101:
1653–1659.
66. Sato A, Terata K, Miura H, Toyama K, Loberiza FR Jr, Hatoum OA et al.
Mechanism of vasodilation to adenosine in coronary arterioles from
patients with heart disease. Am J Physiol Heart Circ Physiol 2005;
288:H1633–H1640.
67. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ et al. Essen-
tial role of the NADPH oxidase subunit p47(phox) in endothelial cell
superoxide production in response to phorbol ester and tumor necrosis
factor-alpha. Circ Res 2002;90:143–150.
68. Liu Y, Terata K, Rusch NJ, Gutterman DD. High glucose impairs voltage-
gated K(þ) channel current in rat small coronary arteries. Circ Res
2001;89:146–152.
69. Hachamovitch R, Berman DS, Kiat H, Cohen I, Friedman JD, Shaw LJ.
Value of stress myocardial perfusion single photon emission computed
tomography in patients with normal resting electrocardiograms: an
evaluation of incremental prognostic value and cost-effectiveness. Cir-
culation 2002;105:823–829.
70. Bartel T, Yang Y, Muller S, Wenzel RR, Baumgart D, Philipp T et al. Non-
invasive assessment of microvascular function in arterial hypertension
by transthoracic Doppler harmonic echocardiography. J Am Coll
Cardiol 2002;39:2012–2018.
71. Poelaert JI, Schupfer G. Hemodynamic monitoring utilizing transesopha-
geal echocardiography: the relationships among pressure, ﬂow, and
function. Chest 2005;127:379–390.
72. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of
short-term treatment of hyperlipidemia on coronary vasodilator func-
tion and myocardial perfusion in regions having substantial impairment
of baseline dilator reverse. Circulation 1998;98:1291–1296.
73. Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P
et al. Abnormal subendocardial perfusion in cardiac syndrome X
detected by cardiovascular magnetic resonance imaging. N Engl J Med
2002;346:1948–1953.
74. Doyle M, Fuisz A, Kortright E, Biederman RW, Walsh EG, Martin ET et al.
The impact of myocardial ﬂow reserve on the detection of coronary
artery disease by perfusion imaging methods: an NHLBI WISE study.
J Cardiovasc Magn Reson 2003;5:475–485.
75. Wagner B, Anton M, Nekolla SG, Reder S, Henke J, Seidl S et al. Nonin-
vasive characterization of myocardial molecular interventions by inte-
grated positron emission tomography and computed tomography. J Am
Coll Cardiol 2006;48:2107–2115.
76. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr,
Lerman A. Long-term follow-up of patients with mild coronary artery
disease and endothelial dysfunction. Circulation 2000;101:948–954.
77. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary
vasodilator dysfunction on adverse long-term outcome of coronary
heart disease. Circulation 2000;101:1899–1906.
78. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA
et al. Prognostic value of coronary vascular endothelial dysfunction. Cir-
culation 2002;106:653–658.
79. Fearon WF, Nakamura M, Lee DP, Rezaee M, Vagelos RH, Hunt SA et al.
Simultaneous assessment of fractional and coronary ﬂow reserves in
cardiac transplant recipients: Physiologic Investigation for Transplant
Arteriopathy (PITA Study). Circulation 2003;108:1605–1610.
80. Baumgart D, Haude M, Liu F, Ge J, Goerge G, Erbel R. Current concepts
of coronary ﬂow reserve for clinical decision making during cardiac
catheterization. Am Heart J 1998;136:136–149.
81. Kern MJ. Coronary physiology revisited: practical insights from the
cardiac catheterization laboratory. Circulation 2000;101:1344–1351.
82. Siebes M, Verhoeff BJ, Meuwissen M, de Winter RJ, Spaan JA, Piek JJ.
Single-wire pressure and ﬂow velocity measurement to quantify coron-
ary stenosis hemodynamics and effects of percutaneous interventions.
Circulation 2004;109:756–762.
83. Kern MJ, Lerman A, Bech JW, De BB, Eeckhout E, Fearon WF et al. Physio-
logical assessment of coronary artery disease in the cardiac catheterization
laboratory: a scientiﬁc statement from the American Heart Association
Committee on Diagnostic and Interventional Cardiac Catheterization,
Council on Clinical Cardiology. Circulation 2006;114:1321–1341.
84. Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC,
Fitzgerald PJ et al. Novel index for invasively assessing the coronary
microcirculation. Circulation 2003;107:3129–3132.
85. Feigl EO. Coronary physiology. Physiol Rev 1983;63:1–205.
86. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ
et al. TIMI frame count: a quantitative method of assessing coronary
artery ﬂow. Circulation 1996;93:879–888.
87. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH
et al. A randomized trial to evaluate the relative protection against post-
percutaneous coronary intervention microvascular dysfunction, ischemia,
and inﬂammation among antiplatelet and antithrombotic agents: the
PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47:2364–2373.
88. Kuvin JT, Karas RH. Clinical utility of endothelial function testing: ready
for prime time? Circulation 2003;107:3243–3247.
89. Alam TA, Seifalian AM, Baker D. A review of methods currently used for
assessment of in vivo endothelial function. Eur J Vasc Endovasc Surg
2005;29:269–276.
90. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B
et al. Beta-2 adrenergic receptor variants affect resting blood pressure
and agonist-induced vasodilation in young adult Caucasians. Hyperten-
sion 1999;33:1425–1430.
91. Park JS, Zhang SY, Jo SH, Seo JB, Li L, Park KW et al. Common adrenergic
receptor polymorphisms as novel risk factors for vasospastic angina. Am
Heart J 2006;151:864–869.
92. Bottcher M, Madsen MM, Refsgaard J, Buus NH, Dorup I, Nielsen TTet al.
Peripheral ﬂow response to transient arterial forearm occlusion does not
reﬂect myocardial perfusion reserve. Circulation 2001;103:1109–1114.
93. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F,
Creager MA et al. Guidelines for the ultrasound assessment of
endothelial-dependent ﬂow-mediated vasodilation of the brachial
artery: a report of the International Brachial Artery Reactivity Task
Force. J Am Coll Cardiol 2002;39:257–265.
94. Hansell J, Henareh L, Agewall S, Norman M. Non-invasive assessment of
endothelial function—relation between vasodilatory responses in skin
microcirculation and brachial artery. Clin Physiol Funct Imaging 2004;
24:317–322.
95. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A
reductase inhibitor, improves endothelial function within 1 month. Cir-
culation 1997;95:1126–1131.
96. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dys-
function in essential hypertension: a randomized, double-blind, cross-
over study. Circulation 2001;104:511–514.
97. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dys-
function, oxidative stress, and risk of cardiovascular events in patients
with coronary artery disease. Circulation 2001;104:2673–2678.
Assessing the coronary microcirculation 173
98. Heitzer T, Baldus S, von KY, Rudolph V, Meinertz T. Systemic endothelial
dysfunction as an early predictor of adverse outcome in heart failure.
Arterioscler Thromb Vasc Biol 2005;25:1174–1179.
99. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endo-
thelial dysfunction in patients with acute coronary syndromes: further
evidence for the existence of the ‘vulnerable’ patient. Circulation
2004;110:1926–1932.
100. Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser Doppler
imaging of skin blood ﬂow as a tool to assess endothelial function.
J Cardiovasc Pharmacol 2000;36:640–648.
101. Kvandal P, Stefanovska A, Veber M, Kvernmo HD, Kirkeboen KA. Regu-
lation of human cutaneous circulation evaluated by laser Doppler ﬂow-
metry, iontophoresis, and spectral analysis: importance of nitric oxide
and prostaglandines. Microvasc Res 2003;65:160–171.
102. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA,
Donker AJ et al. Microvascular function relates to insulin sensitivity
and blood pressure in normal subjects. Circulation 1999;99:896–902.
103. Medow MS, Minson CT, Stewart JM. Decreased microvascular nitric
oxide-dependent vasodilation in postural tachycardia syndrome. Circu-
lation 2005;112:2611–2618.
104. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differ-
ential effect of urotensin II on vascular tone in normal subjects and
patients with chronic heart failure. Circulation 2004;109:1212–1214.
105. Pries AR, Secomb TW, Gaehtgens P. Design principles of vascular beds.
Circ Res 1995;77:1017–1023.
106. Zakrzewicz A, Secomb TW, Pries AR. Angioadaptation: keeping the vas-
cular system in shape. News Physiol Sci 2002;17:197–201.
107. Yvonne-Tee GB, Rasool AH, Halim AS, Rahman AR. Noninvasive assess-
ment of cutaneous vascular function in vivo using capillaroscopy,
plethysmography and laser-Doppler instruments: its strengths and
weaknesses. Clin Hemorheol Microcirc 2006;34:457–473.
108. Hern S, Mortimer PS. Visualization of dermal blood vessels—capillaro-
scopy. Clin Exp Dermatol 1999;24:473–478.
109. Scardina GA, Messina P. Morphologic changes in the microcirculation
induced by chronic smoking habit: a videocapillaroscopic study on the
human gingival mucosa. Am J Dent 2005;18:301–304.
110. Groner W, Winkelman JW, Harris AG, Ince C, Bouma GJ, Messmer K et al.
Orthogonal polarization spectral imaging: a new method for study of the
microcirculation. Nat Med 1999;5:1209–1212.
111. Lindert J, Werner J, Redlin M, Kuppe H, Habazettl H, Pries AR. OPS
imaging of human microcirculation: a short technical report. J Vasc
Res 2002;39:368–372.
112. Habazettl H, Kukucka M, Weng YG, Kuebler WM, Hetzer R, Kuppe H
et al. Arteriolar blood ﬂow pulsatility in a patient before and after
implantation of an axial ﬂow pump. Ann Thorac Surg 2006;81:
1109–1111.
113. Cuspidi C, Meani S, Salerno M, Fusi V, Severgnini B, Valerio C et al.
Retinal microvascular changes and target organ damage in untreated
essential hypertensives. J Hypertens 2004;22:2095–2102.
114. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G et al. Inﬂu-
ence of metabolic syndrome on hypertension-related target organ
damage. J Intern Med 2005;257:503–513.
115. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM et al.
Retinal arteriolar narrowing and risk of coronary heart disease in men
and women. The Atherosclerosis Risk in Communities Study. JAMA
2002;287:1153–1159.
116. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD et al.
Retinal microvascular abnormalities and incident stroke: the Athero-
sclerosis Risk in Communities Study. Lancet 2001;358:1134–1140.
117. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G
et al. Relations between cardiac and vascular structure in patients
with primary and secondary hypertension. J Am Coll Cardiol 1998;32:
985–992.
118. Rizzoni D, Agabiti RE. Small artery remodeling in hypertension and
diabetes. Curr Hypertens Rep 2006;8:90–95.
119. Erbs S, Linke A, Adams V, Lenk K, Thiele H, Diederich KW et al.
Transplantation of blood-derived progenitor cells after recanalization
of chronic coronary artery occlusion: ﬁrst randomized and placebo-
controlled study. Circ Res 2005;97:756–762.
120. Schachinger V, Assmus B, Honold J, Lehmann R, Hofmann WK, Martin H
et al. Normalization of coronary blood ﬂow in the infarct-related artery
after intracoronary progenitor cell therapy: intracoronary Doppler
substudy of the TOPCARE-AMI trial. Clin Res Cardiol 2006;95:13–22.
A.R. Pries et al.174
